SUNNYVALE, Calif., Feb. 25, 2020 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) announced today that Mercy Hospital St.
Louis continues to demonstrate its commitment to improving patient
outcomes with the installation of the first CyberKnife®
M6™ System in Missouri at their
state-of-the-art David C. Pratt Cancer Center. The next-generation
CyberKnife System has been shown to deliver precise
stereotactic radiosurgery (SRS) and stereotactic body radiation
therapy (SBRT) treatments with ease, making it possible for the
clinical team to expand access to one of the most advanced methods
for administering radiation to more cancer patients.
SRS and SBRT are non-invasive forms of radiation therapy that
use high doses of very targeted radiation to destroy tumors, in
just a few treatment sessions (1 to 5). SRS is commonly used to
treat conditions within the brain and spine, while SBRT is used for
those tumors located outside these areas. The CyberKnife M6 System
is equipped with sophisticated functionality that will streamline
the creation of personalized treatment plans and reduce the time to
deliver radiation treatments, enabling the Mercy St. Louis team to
offer precision SRS and SBRT treatments to more patients each
day.
The Mercy Hospital St. Louis team uses the most advanced
radiotherapy technology to design and deliver an individualized
treatment plan designed to help cancer patients take control of
their disease and resume their lives. The hospital is part of the
Mercy system, named one of the top five large U.S. health systems
from 2016 to 2019 by IBM Watson Health. Mercy announced in 2018
that it intended to work with Accuray to enhance cancer care
through advanced life-saving technology, including the CyberKnife
System that was recently installed as well as Accuray
Radixact® Systems that will be installed at other Mercy
hospitals.
"The CyberKnife M6 is really an ideal system for the hospital
and for our patients. The system combines sub-millimeter accuracy
with real-time image guidance, enabling our team to effectively
treat almost any part of the body requiring radiation therapy,"
said Robert Frazier, M.D., radiation
oncologist and division chief for radiation oncology at Mercy
Hospital St. Louis. "For example, when we treat patients with brain
tumors, we will now be able to deliver a very high dose of
radiation to the tumor, to eradicate the disease, while minimizing
the dose to critical brain structures. Prostate cancer patients who
would have been treated with daily radiation equal to 40-45
fractions over 8-9 weeks, can now be treated in just 5 fractions
with the CyberKnife System. And, because CyberKnife prostate SBRT
typically is associated with few side effects, these patients can
return to their normal activity on the same day."
Click here to see how the CyberKnife System treats brain tumors
and here to see the system treat prostate cancer.
"We congratulate the Mercy Hospital St. Louis team on the
installation of their CyberKnife M6 System. We are committed to
supporting them in their goal to expand access to advanced
radiotherapy. This most recent installation of the CyberKnife M6
System further demonstrates clinicians' confidence in the value the
system will bring to their patients, their team and their
hospital," said Joshua H. Levine,
president and CEO at Accuray.
Important Safety Information
For Important Safety Information please refer to
https://www.accuray.com/safety-statement.
About the CyberKnife System
The CyberKnife System is the only robotic radiosurgery system that
offers highly precise, non-surgical treatment for tumors and
lesions anywhere in the body—including the brain, breast, kidney,
liver, lung, pancreas, prostate and spine. The CyberKnife System
tracks and automatically adjusts for tumor or patient movement
during treatment, delivering the radiation dose directly to the
target with sub-millimeter precision. Synchrony® motion
tracking and correction technology expands on the CyberKnife
System's unique motion synchronization capabilities to provide
additional precision when treating tumors that move with
respiration. The high level of accuracy in dose delivery made
possible by the system gives clinical teams the confidence to
deliver state-of-the-art treatments for a wide range of cancers and
functional disorders, without sacrificing patients' quality of
life.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) develops, manufactures and
sells radiotherapy systems that are intended to make cancer
treatments shorter, safer, personalized and more effective,
ultimately enabling patients to live longer, better lives. Our
radiation treatment delivery systems in combination with
fully-integrated software solutions set the industry standard for
precision and cover the full range of radiation therapy and
radiosurgery procedures. For more information, please visit
www.accuray.com or follow us on Facebook, LinkedIn, Twitter and
YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to the anticipated
installation of Radixact Systems at other Mercy hospitals, clinical
applications, clinical results, patient experiences, patient
outcomes and the company's ability to continue to penetrate the
global radiation therapy market. These forward-looking statements
involve risks and uncertainties. If any of these risks or
uncertainties materialize, or if any of the company's assumptions
prove incorrect, actual results could differ materially from the
results expressed or implied by these forward-looking
statements. These risks and uncertainties include, but are not
limited to, the company's ability to achieve widespread market
acceptance of its products; the company's ability to develop new
products or improve existing products to meet customers' needs; the
company's ability to anticipate or keep pace with changes in the
marketplace and the direction of technological innovation and
customer demands and such other risks identified under the heading
"Risk Factors" in the company's quarterly report on Form 10-Q,
filed with the Securities and Exchange Commission (the "SEC") on
February 4, 2020, and as updated
periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media Contacts
Beth
Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
Jayme Maniatis
MSLGROUP
+1 (781) 684-6610
accuray@mslgroup.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/first-accuray-cyberknife-m6-system-installed-in-missouri-at-mercy-hospital-st-louis-301010448.html
SOURCE Accuray Incorporated